Heinrich-Heine University, Duesseldorf
hhu.deLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
177
Active
49
Phase 3
4
Total enrollment
55,464
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin | — | — | — | — | — | 1 | |
| Autologous, tumor lysate-loaded, mature dendritic cells | — | — | — | — | — | 1 | |
| standard therapy | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Amsacrine | — | — | — | — | — | 1 | |
| Ara-C | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Mycophenolate Mofetil | — | — | — | — | — | 1 | |
| Anti-CD20 antibody | — | — | — | — | — | 1 |
Next readouts
- 2026-01-31
- 2026-08-31
- 2027-05
- 2028-12-31
Top conditions
- Prostate Cancer8
- Schizophrenia8
- Cardiovascular Diseases5
- Multiple Sclerosis4
- Heart Failure3
- Healthy3
- Heart Transplantation3
- Myelodysplastic Syndromes3
Frequently asked questions about Heinrich-Heine University, Duesseldorf
- How many clinical trials does Heinrich-Heine University, Duesseldorf have on ClinicalTrials.gov?
- Heinrich-Heine University, Duesseldorf is listed as the lead sponsor on 177 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Heinrich-Heine University, Duesseldorf's trials are in Phase 3?
- 4 of Heinrich-Heine University, Duesseldorf's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does Heinrich-Heine University, Duesseldorf focus on?
- Heinrich-Heine University, Duesseldorf's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Schizophrenia, Cardiovascular Diseases, Multiple Sclerosis, Heart Failure.
- When are Heinrich-Heine University, Duesseldorf's next clinical trial readouts?
- Heinrich-Heine University, Duesseldorf has 4 upcoming primary-completion readouts tracked here; the soonest is “Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML”, expected around 2026-01-31.